Literature DB >> 26998087

B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer.

Hong Xu1, Xiaoling Chen2, Min Tao1, Kai Chen1, Chen Chen3, Gang Xu3, Wei Li1, Suxu Yuan1, Yixiang Mao1.   

Abstract

B7-H3 and B7-H4 belong to the peripheral membrane protein B7 family and are hypothesized to regulate immunity. These proteins are expressed in human pancreatic cancer (PC), but their prognostic significance is poorly understood. The present study examined the association between B7-H3 and B7-H4 expression and the overall survival time in patients with PC that underwent surgery at the Second Affiliated Hospital to Zhengzhou University between April 2000 and January 2009. Immunohistochemical analysis demonstrated that B7-H3 and B7-H4 were expressed in 35 (88%) and 30 (75%) tumor tissue samples, respectively, which were obtained from 40 patients with PC. Statistical analysis revealed that B7-H3 expression was associated with an early tumor-node-metastasis stage (stage I and II; P<0.01), and B7-H4 expression was associated with tumors located in the body and tail of the pancreas (P<0.01) and lymph node metastasis (P=0.02). In addition, using Spearman's rank correlation coefficient, the present study demonstrated a positive correlation between B7-H3 expression and B7-H4 expression (r=0.37; P=0.02) in tumor samples. B7-H4 expression (P=0.01), tumors located in the pancreatic body and tail (P<0.01), lymph node metastasis (P=0.02) and combined B7-H3 and B7-H4 expression (P<0.01) were indicators of a poor overall survival time. However, solitary B7-H4 expression (P=0.03) and combined B7-H3 and B7-H4 expression (P=0.04) remained significant prognostic factors following adjustment for other prognostic factors in a multivariate Cox's proportional hazards regression model. Therefore, the present results indicate that solitary B7-H4 expression and a combination of B7-H3 and B7-H4 expression are independent predictors of a poor prognosis in patients with PC.

Entities:  

Keywords:  B7-H3; B7-H4; immunohistochemistry; pancreatic cancer; prognosis

Year:  2016        PMID: 26998087      PMCID: PMC4774460          DOI: 10.3892/ol.2016.4128

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

Review 1.  The balance of immune responses: costimulation verse coinhibition.

Authors:  Sumit K Subudhi; Maria-Luisa Alegre; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

Review 2.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  B7-h4 is highly expressed in ductal and lobular breast cancer.

Authors:  Barbara Tringler; Shaoqiu Zhuo; Glenn Pilkington; Kathleen C Torkko; Meenakshi Singh; M Scott Lucia; David E Heinz; Jackie Papkoff; Kenneth R Shroyer
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

4.  B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.

Authors:  Iris Simon; Dionyssios Katsaros; Irene Rigault de la Longrais; Marco Massobrio; Andreas Scorilas; Nam W Kim; Mark J Sarno; Robert L Wolfert; Eleftherios P Diamandis
Journal:  Gynecol Oncol       Date:  2007-05-11       Impact factor: 5.482

Review 5.  A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.

Authors:  Janelle M Fauci; J Michael Straughn; Soldano Ferrone; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2012-08-19       Impact factor: 5.482

6.  B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration.

Authors:  Kimberly C Mugler; Meenakshi Singh; Barbara Tringler; Kathleen C Torkko; Wenhui Liu; Jackie Papkoff; Kenneth R Shroyer
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-12

Review 7.  Fine tuning the immune response through B7-H3 and B7-H4.

Authors:  Kyung H Yi; Lieping Chen
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

8.  Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Authors:  Nida S Awadallah; Kenneth R Shroyer; Daniel A Langer; Kathleen C Torkko; Yang K Chen; Joel S Bentz; Jackie Papkoff; Wenhui Liu; S Russell Nash; Raj J Shah
Journal:  Pancreas       Date:  2008-03       Impact factor: 3.327

9.  B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.

Authors:  Timothy J Roth; Yuri Sheinin; Christine M Lohse; Susan M Kuntz; Xavier Frigola; Brant A Inman; Amy E Krambeck; Maureen E McKenney; R Jeffrey Karnes; Michael L Blute; John C Cheville; Thomas J Sebo; Eugene D Kwon
Journal:  Cancer Res       Date:  2007-08-08       Impact factor: 12.701

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  18 in total

1.  Involvement of soluble B7-H3 in combination with the serum inflammatory cytokines interleukin-17, -8 and -6 in the diagnosis of hepatocellular carcinoma.

Authors:  Fenghuang Xu; Junzhu Yi; Feifei Wang; Weiwei Wang; Zhuoya Wang; Jiangnan Xue; Xiying Luan
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

2.  HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.

Authors:  Han Yan; Wanglong Qiu; Anne K Koehne de Gonzalez; Ji-Shu Wei; Min Tu; Chun-Hua Xi; Ye-Ran Yang; Yun-Peng Peng; Wei-Yann Tsai; Helen E Remotti; Yi Miao; Gloria H Su
Journal:  Cancer Lett       Date:  2018-11-14       Impact factor: 8.679

3.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors:  Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

4.  The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma.

Authors:  Till Sebastian Clauditz; Thorsten Rieckmann; Mara Borgmann; Agnes Oetting; Felix Meyer; Nikolaus Möckelmann; Conrad Droste; Clara Marie von Bargen; Christina Möller-Koop; Melanie Witt; Kerstin Borgmann; Kai Rothkamm; Christian Betz; Adrian Münscher
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-08       Impact factor: 4.322

Review 5.  Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.

Authors:  Xiaoxin Ren; Yixian Li; Christopher Nishimura; Xingxing Zang
Journal:  Genes Dis       Date:  2021-09-20

Review 6.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

Review 7.  New B7 Family Checkpoints in Human Cancers.

Authors:  Ling Ni; Chen Dong
Journal:  Mol Cancer Ther       Date:  2017-07       Impact factor: 6.261

8.  Comprehensive molecular profiling of the B7 family in gastrointestinal cancer.

Authors:  Qijie Zhao; Fuyan Hu; Zhangang Xiao; Mingxing Li; Xu Wu; Yueshui Zhao; Yuanlin Wu; Jianhua Yin; Ling Lin; Hanyu Zhang; Lingling Zhang; Chi Hin Cho; Jing Shen
Journal:  Cell Prolif       Date:  2018-07-12       Impact factor: 6.831

9.  Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies.

Authors:  Gianluca Tomasello; Michele Ghidini; Antonio Costanzo; Antonio Ghidini; Alessandro Russo; Sandro Barni; Rodolfo Passalacqua; Fausto Petrelli
Journal:  J Gastrointest Oncol       Date:  2019-04

10.  B7-H3 targeted antibody-based immunotherapy of malignant diseases.

Authors:  Theodoros Michelakos; Filippos Kontos; Omar Barakat; Luke Maggs; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2020-12-21       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.